Asahi Kasei Launches Benchtop System to Streamline Gene Therapy Production — Asahi Kasei Corporation

Event summary

Asahi Kasei Bioprocess unveiled the VANTIJ® SU-VFC Benchtop at Bioprocess International East (BPI EAST) 2026, a small-format system for automated, single-use virus filtration in gene therapy manufacturing.
The system is designed for laboratory-scale and process development applications, featuring a compact design accommodating 0.12 m² or 0.3 m² Planova™ 35N virus-removal filters.
The VANTIJ® SU-VFC Benchtop offers guided setup, tool-free installation, intuitive connection points, and recipe-driven software to simplify virus filtration processes.
The launch reflects Asahi Kasei's strategic focus on supporting the growth of cell and gene therapies, a rapidly evolving segment in the biopharmaceutical industry.

The big picture

The launch of the VANTIJ® SU-VFC Benchtop underscores Asahi Kasei's commitment to addressing operational challenges in gene therapy manufacturing, including long production timelines and regulatory complexities. This move aligns with the broader industry trend towards automation and efficiency in biopharmaceutical development, particularly in the rapidly growing cell and gene therapy segment. Asahi Kasei's strategic focus on this area positions it to capitalize on the increasing demand for innovative therapies.

What we're watching

Market Adoption: The pace at which biopharmaceutical companies adopt the VANTIJ® SU-VFC Benchtop will indicate its competitive edge in gene therapy manufacturing.
Regulatory Compliance: Whether the system's automation and data-focused capabilities can help manufacturers meet stringent regulatory requirements for gene therapies.
Strategic Expansion: How Asahi Kasei's focus on cell and gene therapies will shape its long-term growth strategy within the biopharmaceutical sector.